Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes

Dual-sized microparticle system generates suppressive dendritic cells, and prevents and reverses type 1 diabetes in the non-obese diabetic mouse

(2019) Jamal S Lewis et al.   ACS Biomaterials-Science & Engineering

The prevalence of MS in the United States

(2019) Mitchell T. Wallin et al.   NEUROLOGY

Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells

(2019) Kenichiro Furuyama et al.   NATURE

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

(2019) Michael J. Haller et al.   DIABETES

Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation

(2019) Eiji Saito et al.   JOURNAL OF CONTROLLED RELEASE

Nanoparticles Containing an Insulin–ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells

(2019) Braxton L. Jamison et al.   JOURNAL OF IMMUNOLOGY

Targeted delivery of antigen to intestinal dendritic cells induces oral tolerance and prevents autoimmune diabetes in NOD mice

(2018) Yulin Chen et al.   DIABETOLOGIA

Nanoparticle-based approaches to immune tolerance for the treatment of autoimmune diseases

(2018) Pau Serra et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells

(2018) Suchitra Prasad et al.   JOURNAL OF AUTOIMMUNITY

Progressive multifocal leukoencephalopathy after fingolimod treatment

(2018) Joseph R. Berger et al.   NEUROLOGY

Latent, Immunosuppressive Nature of Poly(lactic-co-glycolic acid) Microparticles

(2018) Riley P. Allen et al.   ACS Biomaterials-Science & Engineering

Latent, Immunosuppressive Nature of Poly(lactic-co-glycolic acid) Microparticles

(2018) Riley P. Allen et al.   ACS Biomaterials Science & Engineering

Multiple sclerosis

(2018) Massimo Filippi et al.   Nature Reviews Disease Primers

Targeted delivery of glucocorticoids to macrophages in a mouse model of multiple sclerosis using inorganic-organic hybrid nanoparticles

(2017) Elena Montes-Cobos et al.   JOURNAL OF CONTROLLED RELEASE

In vivo induction of regulatory T cells promotes allergen tolerance and suppresses allergic contact dermatitis

(2017) Stephen C. Balmert et al.   JOURNAL OF CONTROLLED RELEASE

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial

(2017) Ari J Green et al.   LANCET

Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance

(2017) Robert Kuo et al.   MOLECULAR THERAPY

Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates

(2017) Ryan M. Pearson et al.   MOLECULAR THERAPY

An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy

(2017) Derrick P. McCarthy et al.   Nanomedicine-Nanotechnology Biology and Medicine

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012

(2017) Elizabeth J. Mayer-Davis et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

(2017) Daniela Schmid et al.   Nature Communications

Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation

(2017) Catia S. Verbeke et al.   Advanced Healthcare Materials

Type 1 diabetes mellitus

(2017) Anastasia Katsarou et al.   Nature Reviews Disease Primers

Development and Pre-Clinical Evaluation of Recombinant Human Myelin Basic Protein Nano Therapeutic Vaccine in Experimental Autoimmune Encephalomyelitis Mice Animal Model

(2017) Medhat A. Al-Ghobashy et al.   Scientific Reports

Micro and Nano Material Carriers for Immunomodulation

(2016) E. Bracho-Sanchez et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Clemastine Enhances Myelination in the Prefrontal Cortex and Rescues Behavioral Changes in Socially Isolated Mice

(2016) J. Liu et al.   JOURNAL OF NEUROSCIENCE

Hyperforin-loaded gold nanoparticle alleviates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells and upregulating regulatory T cells

(2016) Reza Nosratabadi et al.   Nanomedicine-Nanotechnology Biology and Medicine

Expanding antigen-specific regulatory networks to treat autoimmunity

(2016) Xavier Clemente-Casares et al.   NATURE

Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization

(2016) Charles B. Smarr et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tolerogenic nanoparticles inhibit T cell–mediated autoimmunity through SOCS2

(2016) Ada Yeste et al.   Science Signaling

Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific

(2016) Lisa H. Tostanoski et al.   Cell Reports

Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery

(2016) Feng Mei et al.   eLife

Tolerogenic nanoparticles inhibit T cell–mediated autoimmunity through SOCS2

(2016) Ada Yeste et al.   Science Signaling

Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells

(2015) Michael D. McHugh et al.   BIOMATERIALS

A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice

(2015) Jamal S. Lewis et al.   CLINICAL IMMUNOLOGY

Controlled delivery of a metabolic modulator promotes regulatory T cells and restrains autoimmunity

(2015) Joshua M. Gammon et al.   JOURNAL OF CONTROLLED RELEASE

Treatment of progressive multiple sclerosis: what works, what does not, and what is needed

(2015) Anthony Feinstein et al.   LANCET NEUROLOGY

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

(2015) Jeffrey A. Bluestone et al.   Science Translational Medicine

Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination

(2015) Zhifang Li et al.   Neuroscience Bulletin

A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice

(2015) Young Mee Yoon et al.   Scientific Reports

A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease

(2014) Zoe Hunter et al.   ACS Nano

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

(2014) Michael J. Haller et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study

(2014) Luis J. Cruz et al.   JOURNAL OF CONTROLLED RELEASE

Activation of the STING Adaptor Attenuates Experimental Autoimmune Encephalitis

(2014) H. Lemos et al.   JOURNAL OF IMMUNOLOGY

Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

(2014) Dean M. Wingerchuk et al.   MAYO CLINIC PROCEEDINGS

Treatment of Experimental Autoimmune Encephalomyelitis by Codelivery of Disease Associated Peptide and Dexamethasone in Acetalated Dextran Microparticles

(2014) Kevin J. Peine et al.   MOLECULAR PHARMACEUTICS

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance

(2014) Roberto A. Maldonado et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review

(2014) Renecia A. Watkins et al.   Translational Research

Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis

(2014) Giuseppe Cappellano et al.   VACCINE

Particle platforms for cancer immunotherapy

(2013) Rita Serda   International Journal of Nanomedicine

Regulation of Immune Responses by mTOR

(2012) Jonathan D. Powell et al.   Annual Review of Immunology

Microparticle surface modifications targeting dendritic cells for non-activating applications

(2012) Jamal S. Lewis et al.   BIOMATERIALS

Multiple sclerosis

(2012) Alyssa Nylander et al.   JOURNAL OF CLINICAL INVESTIGATION

Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

(2012) Daniel R Getts et al.   NATURE BIOTECHNOLOGY

Survival in MS

(2012) D.S. Goodin et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis

(2012) A. Yeste et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Susceptibility to gold nanoparticle-induced hepatotoxicity is enhanced in a mouse model of nonalcoholic steatohepatitis

(2012) Jung Hwan Hwang et al.   TOXICOLOGY

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach

(2012) Claudio Gasperini et al.   Drug Design Development and Therapy

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

(2011) Bernd C. Kieseier   CNS DRUGS

TOR in the immune system

(2011) Koichi Araki et al.   CURRENT OPINION IN CELL BIOLOGY

Phase I (Safety) Study of Autologous Tolerogenic Dendritic Cells in Type 1 Diabetic Patients

(2011) N. Giannoukakis et al.   DIABETES CARE

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

(2011) Stephen Sawcer et al.   NATURE

RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation

(2011) Laura Codarri et al.   NATURE IMMUNOLOGY

Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I

(2010) E Snarski et al.   BONE MARROW TRANSPLANTATION

Reversal of Autoimmunity by Boosting Memory-like Autoregulatory T Cells

(2010) Sue Tsai et al.   IMMUNITY

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells

(2010) Roopali Gandhi et al.   NATURE IMMUNOLOGY

Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation

(2010) Francesca Fallarino et al.   NATURE MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism

(2010) N. T. Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis

(2010) F. J. Quintana et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses

(2009) Jun Zhou et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes

(2009) P.-H. Groop et al.   DIABETES

No Effect of the Altered Peptide Ligand NBI-6024 on  -Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes

(2009) M. Walter et al.   DIABETES CARE

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Microsphere-Based Vaccine Prevents and Reverses New-Onset Autoimmune Diabetes

(2008) B. Phillips et al.   DIABETES

Delivery of rapamycin to dendritic cells using degradable microparticles

(2008) S. Jhunjhunwala et al.   JOURNAL OF CONTROLLED RELEASE

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial

(2008) Kirsti Näntö-Salonen et al.   LANCET

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Efficient Modulation of T-cell Response by Dual-mode, Single-carrier Delivery of Cytokine-targeted siRNA and DNA Vaccine to Antigen-presenting Cells

(2008) Ankur Singh et al.   MOLECULAR THERAPY

Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor

(2008) Francisco J. Quintana et al.   NATURE

Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2008) D. S. Goodin et al.   NEUROLOGY

Poly (lactide-co-glycolide)-Polymethacrylate Nanoparticles for Intramuscular Delivery of Plasmid Encoding Interleukin-10 to Prevent Autoimmune Diabetes in Mice

(2008) Ashwin Basarkar et al.   PHARMACEUTICAL RESEARCH

Role of Particle Size in Phagocytosis of Polymeric Microspheres

(2008) Julie A. Champion et al.   PHARMACEUTICAL RESEARCH

TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses

(2008) Eva Schlosser et al.   VACCINE